Published: 18 May 2026 | 5.59 AM
Last Updated: 18 May 2026 | 7.00 AM
IPO Overview / Intro
Bio Medica Laboratories IPO is an SME book build issue comprising a combination of fresh issue and offer for sale. The IPO consists of fresh issue of 34.06 lakh shares and offer for sale of 3.77 lakh shares. The IPO opens for subscription on 21 May 2026 and closes on 25 May 2026. The company is proposed to be listed on the NSE SME platform on 29 May 2026.
Bio Medica Laboratories Ltd. is engaged in manufacturing pharmaceutical parenteral formulations including liquid injectables, dry powder injectables, ethical drugs, generic medicines and OTC pharmaceutical products for both human and veterinary healthcare segments. The company primarily operates on a contract manufacturing B2B model.
👉 | IPO GMP | IPO Reviews | IPO Subscription | IPO Allotment
Key Highlights
| Particulars | Details |
|---|---|
| IPO Type | SME Book Build IPO |
| Issue Size | 37,72,000 Shares |
| Business | Pharmaceutical Injectables |
| Listing Exchange | NSE SME |
| Issue Nature | Fresh Issue + OFS |
| Price Band | To be Announced |
| Retail Application | Yet to be Announced |
| Listing Date | 29 May 2026 |
| Lead Manager | Narnolia Financial Services Ltd. |
| Registrar | Skyline Financial Services Pvt. Ltd. |
Bio Medica Laboratories IPO GMP – Latest Update
| Particulars | Details |
|---|---|
| IPO GMP Today | Rs. NA |
| Kostak | NA |
| Subject to Sauda | NA |
| GMP Trend | Awaited |
Bio Medica Laboratories IPO Subscription Status – Live Update
| Investor Category | Subscription Status |
|---|---|
| QIB | Yet to Open |
| NII | Yet to Open |
| Retail | Yet to Open |
| Total | Yet to Open |
IPO Details at a Glance
| Particulars | Details |
|---|---|
| IPO Date | 21 May to 25 May 2026 |
| Listing Date | 29 May 2026 |
| Face Value | Rs. 10 per share |
| Price Band | To be Announced |
| Lot Size | To be Announced |
| Issue Type | Bookbuilding IPO |
| Sale Type | Fresh Issue cum OFS |
| Listing At | NSE SME |
| Total Issue Size | 37,72,000 Shares |
| Fresh Issue | 32,06,000 Shares |
| Offer for Sale | 3,77,000 Shares |
| Market Maker Portion | 1,89,000 Shares |
| Net Offer to Public | 35,83,000 Shares |
| Shareholding Pre Issue | 91,80,001 Shares |
| Shareholding Post Issue | 1,25,75,001 Shares |
IPO Timetable
| Event | Date |
|---|---|
| IPO Open | Thursday, 21 May 2026 |
| IPO Close | Monday, 25 May 2026 |
| Allotment Finalisation | Tuesday, 26 May 2026 |
| Refund Initiation | Wednesday, 27 May 2026 |
| Credit of Shares | Wednesday, 27 May 2026 |
| Listing Date | Friday, 29 May 2026 |
Reservation
| Investor Category | Shares Offered | % of Net Issue |
|---|---|---|
| QIB Shares Offered | 36,000 | 1.00% |
| NII Shares Offered | 17,55,000 | 48.98% |
| bNII Portion | 11,70,000 | 31.02% |
| sNII Portion | 5,85,000 | 15.51% |
| Retail Shares Offered | 17,92,000 | 50.01% |
| Market Maker Portion | 1,89,000 | 5.01% |
| Total Shares Offered | 37,72,000 | 100.00% |
Lot Size
| Application | Lots | Shares | Amount |
|---|---|---|---|
| Retail (Min) | To be Announced | To be Announced | To be Announced |
| Retail (Max) | To be Announced | To be Announced | To be Announced |
| S-HNI (Min) | To be Announced | To be Announced | To be Announced |
| B-HNI (Min) | To be Announced | To be Announced | To be Announced |
Company Details
Bio Medica Laboratories Ltd., incorporated in August 2015, specialises in manufacturing pharmaceutical parenteral formulations including liquid injectables and dry powder injectables. The company manufactures ethical drugs, generic medicines and OTC pharmaceutical products catering to both human and veterinary healthcare requirements.
The company offers diversified injectable formulations including 58 liquid injectable products and 15 dry powder injectable products. Bio Medica Laboratories operates on a contract manufacturing B2B business model where formulations are developed according to customer specifications and requirements.
The company is certified under GMP and GLP standards issued by Food & Drugs Administration, Madhya Pradesh and operates two manufacturing facilities located in Indore, Madhya Pradesh. Its diversified product portfolio, quality assurance systems and established client relationships remain important strengths for the business.
| Particulars | Details |
|---|---|
| Registered Office | Plot No. 11B-11C, Sector-E, Sanwer Road Industrial Area, Industrial Estate (Indore), Indore, Madhya Pradesh – 452015 |
| Phone | +91-7314102751 |
| companysecretary@biomedica.co.in | |
| Business Segment | Pharmaceutical Manufacturing |
| Core Products | Liquid Injectables, Dry Powder Injectables |
| Business Model | B2B Contract Manufacturing |
| Manufacturing Facilities | 2 Facilities |
| Certifications | GMP & GLP Certified |
| Particulars | Details |
|---|---|
| Lead Manager | Narnolia Financial Services Ltd. |
| Registrar | Skyline Financial Services Pvt. Ltd. |
Financials
| Particulars (Rs. Cr.) | Nov 2025 | FY25 | FY24 | FY23 |
|---|---|---|---|---|
| Assets | 65.17 | 39.12 | 19.53 | 17.57 |
| Total Income | 28.63 | 38.33 | 15.34 | 16.25 |
| Profit After Tax | 8.66 | 9.79 | 2.50 | 0.33 |
| EBITDA | 13.45 | 15.21 | 5.63 | 1.70 |
| Net Worth | 17.12 | 14.73 | 4.94 | 2.44 |
| Reserves & Surplus | 7.94 | 5.55 | 4.84 | 2.34 |
| Total Borrowings | 38.17 | 15.01 | 10.49 | 9.61 |
Valuation
| Objects of the Issue | Estimated Amount (Rs. Cr.) |
|---|---|
| Repayment of Loan | 6.50 |
| New Manufacturing Facility Expansion | 28.50 |
| General Corporate Purpose | Balance |
| Total | 35.00 |
| KPI | FY25 |
|---|---|
| ROE | 99.59% |
| ROCE | 48.20% |
| Debt/Equity | 1.02 |
| RoNW | 99.59% |
| PAT Margin | 25.64% |
| EBITDA Margin | 39.83% |
| Particulars | Pre IPO | Post IPO |
|---|---|---|
| Promoter Holding | 99.99% | NA |
| Market Cap | To be Announced | NA |
Chanakya View
Bio Medica Laboratories IPO operates in the pharmaceutical injectables and contract manufacturing segment where long-term industry demand remains supported by rising healthcare spending, growing generic drug demand and expansion in domestic pharmaceutical manufacturing capabilities.
The company has demonstrated sharp financial improvement with strong profitability growth, expanding EBITDA margins and improving scale of operations. Its diversified injectable portfolio, GMP-certified manufacturing facilities and B2B contract manufacturing model remain key positives for scalability.
However, investors should also monitor risks associated with regulatory compliance, customer concentration, competitive pharmaceutical pricing and relatively higher leverage position. SME pharmaceutical companies also remain sensitive to regulatory observations and working capital cycles.
| Parameter | Chanakya View |
|---|---|
| Business Model | Pharma Injectables |
| Financial Trend | Strong Growth |
| Margin Profile | Strong |
| Valuation | Awaited |
| Risk Level | Moderate to High |
| Listing Appeal | Positive |
| Long-Term Appeal | Positive |
Chanakya View: Bio Medica Laboratories IPO appears to be a fast-growing pharmaceutical SME IPO with strong profitability profile and scalable injectable manufacturing business. The company’s contract manufacturing model, expanding product portfolio and improving financial performance make it an interesting SME healthcare play for investors with moderate-to-high risk appetite.
Frequently Asked Questions (FAQs)
What is Bio Medica Laboratories IPO GMP today?
Bio Medica Laboratories IPO GMP today is currently unavailable in the grey market. GMP activity may emerge closer to the IPO listing date.
What is the Bio Medica Laboratories IPO price band?
The Bio Medica Laboratories IPO price band is yet to be officially announced by the company.
What is the Bio Medica Laboratories IPO lot size?
The minimum lot size for Bio Medica Laboratories IPO is yet to be announced.
When will Bio Medica Laboratories IPO list?
Bio Medica Laboratories IPO is scheduled to list on the NSE SME platform on 29 May 2026.